Methylphenidate - UCB

Drug Profile

Methylphenidate - UCB

Alternative Names: Equasym; Metadate; Metadate CD; Metadate ER; Methylphenidate MR racemate; SPD 544

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator UCB
  • Developer Shire; UCB
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 10 Aug 2011 Shire plans to launch Equasym® in additional countries in the EU
  • 17 Aug 2009 Launched for Attention-deficit hyperactivity disorder in Denmark (PO)
  • 17 Aug 2009 Launched for Attention-deficit hyperactivity disorder in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top